Physician profile
Sharda Ramsaroop
NPI 1043290208
$2,482.81
in general payments reported to CMS, 2019-2025
22 companies · $125 in 2025
The $125 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $335 · 2021: $421 · 2022: $381 · 2023: $765 · 2024: $228 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $615.30 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $324.66 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $322.54 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $191.05 | 2021-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $110.24 | 2019-2021 | |
| Astellas Pharma US INC | $107.38 | 2020-2024 | Veozah |
| Amgen INC. | $105.25 | 2019-2023 | Otezla, Repatha |
| Abbvie INC. | $100.08 | 2022-2024 | |
| Lilly USA, LLC | $92.02 | 2021-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $76.31 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.99 | 2021-2023 | Jardiance, Tradjenta, Glyxambi |
| Daiichi Sankyo INC. | $45.59 | 2020 | |
| Pfizer INC. | $44.64 | 2019-2023 | |
| Hologic Sales and Service, LLC | $37.50 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $23.21 | 2020 | |
| Redhill Biopharma INC. | $22.44 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.49 | 2023 | |
| Bausch Health US, LLC | $19.28 | 2020 | |
| Genentech USA, INC. | $17.72 | 2019 | |
| Currax Pharmaceuticals LLC | $17.34 | 2023 | Contrave, Nexletol, Nexlizet |
| Teva Pharmaceuticals USA, INC. | $16.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharda Ramsaroop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.